News

Eli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight loss

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.

Eli Lilly's obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

Stocks to Watch Thursday: Eli Lilly, Broadcom, DoorDash, TSMC

Shares of the iPhone maker rose nearly 3%, building on the previous session's rally. Apple announced an extra $100 billion ...

Eli Lilly to sell troubled N.J. pharmaceutical plant, but says jobs are safe. Here’s why.

Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...

Eli Lilly beats earnings for second quarter on strong GLP-1 sales, stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
BioSpace2h

Lilly’s Hotly Anticipated Oral Weight Loss Drug Delivers Lukewarm Results in Phase III

Lilly’s orforglipron cut body weight as expected in the Phase III ATTAIN-1 trial, but to a lesser extent than rival Novo ...
Fierce Biotech3h

Eli Lilly shakes up pain pipeline as part of quarterly R&D clearout

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Mounjaro appears more heart protective than Trulicity in trial of Eli Lilly diabetes drugs

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...